Skip to Content
Merck
CN
  • [Long-term results and perspectives of various radio-endovascular embolization in the treatment of patients with renal parenchyma cancer].

[Long-term results and perspectives of various radio-endovascular embolization in the treatment of patients with renal parenchyma cancer].

Vestnik rentgenologii i radiologii (1993-09-01)
A M Granov, V N Anisimov, M I Karelin, A Iu Zakharov, I A Shumskiĭ
ABSTRACT

Various types of x-ray endovascular embolization were carried out in 256 patients with renal parenchymatous carcinoma over the period of 1979 to 1991. Iodolipol chemoembolization with dioxadet, a fat-soluble preparation, significantly improved three- and five-year cumulative survival of operable patients to 82.5 and 77%, respectively, vs. embolization without dioxadet, when only 58% of patients survived for three and 51% for five years. In inoperable patients five-year survival after fatty chemoembolization was 24.5% vs. null in the group administered embolization without dioxadet. Ferrochemoembolization appears still more promising.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Barium ferrite, nanopowder, <100 nm particle size (BET), >97% trace metals basis